Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double‐blind study of denosumab and zoledronic acid

Cleeland, Charles S., Body, Jean‐Jacques, Stopeck, Alison, von Moos, Roger, Fallowfield, Lesley, Mathias, Susan D., Patrick, Donald L., Clemons, Mark, Tonkin, Katia, Masuda, Norikazu, Lipton, Allan, de Boer, Richard, Salvagni, Stefania, Oliveira, Celia Tosello, Qian, Yi, Jiang, Qi, Dansey, Roger, Braun, Ada, Chung, Karen · 2013 · Cancer

Abstract

BACKGROUND: In this study, the authors evaluated the effect of denosumab versus zoledronic acid (ZA) on pain in patients with advanced breast cancer and bone metastases. METHODS: The prevention of pain, reduction in pain interference with daily life activities, and the proportion of patients requiring strong opioid analgesics were assessed in a randomized, double‐blind, double‐dummy phase 3 study comparing denosumab with ZA for preventing skeletal‐related events in 2046 patients who had breast cancer and bone metastases. Patients completed the Brief Pain Inventory‐Short Form at baseline and monthly thereafter. RESULTS: Fewer patients who received denosumab reported a clinically meaningful worsening of pain severity (≥2‐point increase) from baseline compared with patients who received ZA, and a trend was observed toward delayed time to pain worsening with denosumab versus ZA (denosumab, 8.5 months; ZA, 7.4 months; P = .08). In patients who had no/mild pain at baseline, a 4‐month delay in progression to moderate/severe pain was observed with denosumab compared with ZA (9.7 months vs 5.8 months; P = .002). Denosumab delayed the time to increased pain interference by approximately 1 month compared with ZA (denosumab, 16.0 months; ZA, 14.9 months; P = .09). The time to pain improvement ( P = .72) and the time to decreased pain interference ( P = .92) were similar between the groups. Fewer denosumab‐treated patients reported increased analgesic use from no/low use at baseline to strong opioid use. CONCLUSIONS: Denosumab demonstrated improved pain prevention and comparable pain palliation compared with ZA. In addition, fewer denosumab‐treated patients shifted to strong opioid analgesic use. Cancer 2013. © 2012 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.27789

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 159

Metadata

Authors
Cleeland, C. S., Body, J., Stopeck, A., von Moos, R., Fallowfield, L., Mathias, S. D., Patrick, D. L., Clemons, M., Tonkin, K., Masuda, N., Lipton, A., de Boer, R., Salvagni, S., Oliveira, C. T., Qian, Y., Jiang, Q., Dansey, R., Braun, A., & Chung, K.
Venue
Cancer
Publisher
Wiley
Published
2012-09-05
Volume
119
Issue
4
Pages
832-838
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1607511023
Cited by
159
References
2
FWCI
6.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double‐blind study of denosumab and zoledronic acid. https://app.cochat.ai/papers/10.1002/cncr.27789
The paper
Cleeland, C. S., Body, J., Stopeck, A., von Moos, R., Fallowfield, L., Mathias, S. D., Patrick, D. L., Clemons, M., Tonkin, K., Masuda, N., Lipton, A., de Boer, R., Salvagni, S., Oliveira, C. T., Qian, Y., Jiang, Q., Dansey, R., Braun, A., & Chung, K. (2013). Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer. https://doi.org/10.1002/cncr.27789

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.